Biomarker-Driven Therapy for NSCLC: Experts Discuss Current and Future Trends

Join us for this dynamic, livestream, CME-certified Webinar to get up to date on new and emerging biomarkers for personalized therapy in lung cancer, including a review of the latest clinical data on predictive biomarkers guiding optimal use of targeted therapies and immunotherapies, discussion of patient cases, and the opportunity to get your questions answered by the experts.

Sign up now!

This symposium is sponsored by Clinical Care Options, LLC and supported by grants from Amgen, Lilly, and Regeneron Pharmaceuticals, Inc. This is not an official program of the American Association for Cancer Research Annual Meeting.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


  • Welcome and Introduction
  • Leveraging New and Emerging Predictive Biomarkers for Targeted Therapies in NSCLC
  • Current and Emerging Biomarkers Predicting Response to Immune-Based Therapies to Guide Precision Treatment Decisions
  • Clinical Pearls: Optimizing Molecular Profiling/Precision Medicine in Lung Cancer
  • Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Nathan Pennell, MD, PhD

Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Jamie Chaft, MD

Assistant Attending Physician
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Stephen V. Liu, MD

Associate Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Goal Statement
The goal of this activity is to educate physicians and other healthcare professionals about the recent improvements in the care of NSCLC and applying those improvements to their patients.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess new and emerging predictive biomarkers to guide precision treatment decisions in patients with NSCLC
  • Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays and other nuances
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Identify patients eligible for ongoing clinical trials of emerging biomarkers for NSCLC


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.